第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届监事会第十次会议通 知于 2025 年 8 月 11 日以邮件方式发出。会议于 2025 年 8 月 21 日在公司上海分公司会 议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会议应出席监事 3 人，实 际出席监事 3 人。会议由监事会主席金桃女士召集并主持，公司董事会秘书列席了会议。 本次会议的召集、召开符合《中华人民共和国公司法》等有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 经与会监事认真审议，通过如下议案： 1. 审议通过《公司 2025 年半年度报告及其摘要》 证券代码：300357 证券简称：我武生物 公告编号：2025-028 号 浙江我武生物科技股份有限公司 具体内容详见公司在深圳证券交易所网站和符合中国证监会规定条件的媒体上同 日披露的《关于续聘会计师事务所的公告》。 表决结果：赞成：3 票；反对：0 票；弃权：0 票 本 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-027 号 浙江我武生物科技股份有限公司 1. 审议通过《公司 2025 年半年度报告及其摘要》 《公司 2025 年半年度报告》及《公司 2025 年半年度报告摘要》的编制和审核程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案报告中的财务信息已经审计委员会审议通过。 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第十三次会议 通知于 2025 年 8 月 11 日以邮件方式发出。会议于 2025 年 8 月 21 日在公司上海分公司 会议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会议应出席董事 6 人， 实际出席董事 6 人。会议由董事长胡赓熙先生召集并主持，公司部分监事、高级管理人 员列席了会议。本次会议的召集、召开符合《中华人民共和国公司法》等有关法律、 ...

Financial Performance - The company's operating revenue for the current reporting period is ¥484,236,510.36, representing a 12.81% increase compared to ¥429,257,047.81 in the same period last year[28]. - Net profit attributable to shareholders of the listed company is ¥177,008,721.63, an increase of 18.61% from ¥149,230,994.02 in the previous year[28]. - The net cash flow from operating activities is ¥200,515,852.10, showing a significant increase of 96.08% compared to ¥102,261,817.01 in the same period last year[28]. - Basic earnings per share are ¥0.3381, up 18.63% from ¥0.2850 in the previous year[28]. - Total assets at the end of the reporting period are ¥2,790,077,042.44, a 2.99% increase from ¥2,709,124,934.20 at the end of the previous year[28]. - The net assets attributable to shareholders of the listed company are ¥2,467,880,978.57, reflecting a 4.85% increase from ¥2,353,706,702.01 at the end of the previous year[28]. - The company achieved operating revenue of ¥484,236,510.36, a year-on-year increase of 12.81%[55]. - The net profit attributable to shareholders was ¥177,008,721.63, reflecting an 18.61% increase compared to the previous year[55]. - Sales revenue from dust mite drops reached ¥454,655,215.07, up 10.51% year-on-year[55]. - Sales revenue from mugwort pollen sublingual drops was ¥21,020,536.26, showing a significant growth of 71.37%[55]. - Sales revenue from skin prick solution increased by 104.38% to ¥6,327,765.88[55]. Product Development and Innovation - The company plans to enhance the promotion of new products such as "Artemisia Flower Pollen Sublingual Drops" and "Artemisia Flower Pollen Skin Prick Liquid" to mitigate risks associated with product concentration[11]. - The company emphasizes the importance of rigorous project initiation processes to accelerate the development of new drugs and minimize associated risks[12]. - The company is focusing on the development of natural drugs to combat antibiotic resistance, addressing a critical public health challenge due to the rise of multi-drug resistant bacteria[43]. - The company has a strong commitment to research and innovation in the field of natural drugs, leveraging China's rich biological resources and traditional medicine practices[43]. - The company is actively expanding into the stem cell field, supported by recent regulatory improvements and a significant market potential, with various policies promoting the development of the stem cell industry[41]. - The company is focusing on R&D investments in its core business while also expanding into other technological fields[90]. - The company has received approval for the clinical trial of "Dermatitis Diagnostic Patch 02," expanding its product pipeline in allergy diagnostics[91]. - The company aims to meet the allergen detection needs of various allergic disease patients through its expanded product offerings[141]. - The company is focused on developing new products in the allergy diagnosis field to address diverse patient needs[141]. Regulatory Environment and Compliance - The pharmaceutical industry faces increasing regulatory scrutiny, which may impact operational models and competitive dynamics[5]. - The company is committed to complying with industry regulations and will actively monitor policy changes to manage operational risks[7]. - New drug development is subject to lengthy regulatory processes, which could delay market entry and affect competitiveness[12]. - The regulatory environment for the biopharmaceutical industry in China is becoming more stringent, which may impact the research, production, and sales processes of pharmaceutical companies[39]. - The company is committed to compliance and risk management strategies to mitigate the impact of price reductions in drug tenders[82]. - The company has implemented a governance framework to enhance operational efficiency and risk management[93]. - The company emphasizes compliance with information disclosure regulations to ensure transparency and fairness for all investors[95]. Market Position and Strategy - The company maintains a leading position in the sublingual desensitization treatment market, with only its "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" approved for nationwide sale in China[40]. - The company reported a significant focus on enhancing existing product promotion to ensure sustainable growth despite external challenges[9]. - The company is exploring alternative sales channels to stabilize prices in response to bidding price reductions and other cost-control measures[8]. - The company’s competitive capabilities in the allergen product sector remain strong, with no significant changes in its market position[40]. - The company’s sublingual desensitization therapy has been increasingly recognized by clinical practitioners, with guidelines recommending it as a first-line treatment for allergic rhinitis and asthma[39]. - The company has established a robust quality control system, with a dedicated quality department overseeing the entire production process[54]. - The company’s marketing strategy focuses on regions with higher prevalence of allergic diseases, leveraging the seasonal nature of its products[53]. Financial Management and Investments - Research and development investment amounted to ¥61,682,073.51, accounting for 12.74% of total revenue, indicating a continued focus on innovation[61]. - The company has a total of 13 valid Chinese invention patents and 7 foreign invention patents, reflecting its strong commitment to intellectual property and innovation[61]. - The company has received an A rating for information disclosure from the Shenzhen Stock Exchange for three consecutive years[95]. - The company has distributed over ¥900 million in cash dividends since its listing, exceeding four times the initial fundraising amount[92]. - The company aims to maintain a profit distribution policy where cash dividends are greater than 30% of the net profit attributable to shareholders each year[92]. - The company has established a supplier evaluation team and management measures to maintain long-term stable relationships with quality suppliers[109]. Social Responsibility and Sustainability - The company is committed to sustainable development and social responsibility, aligning its strategies with the interests of employees and society[102]. - The company has initiated a patient assistance project to provide sublingual desensitization medication to children and adults suffering from allergic rhinitis, with a donation agreement signed with the Beijing Kangmeng Charity Foundation[113]. - The project aims to improve medication efficacy and adherence for patients with allergic rhinitis caused by mugwort pollen, reducing their economic burden[114]. - The company has committed to a green office initiative, promoting paperless operations to enhance environmental awareness among employees[111]. - The company has not experienced any major pollution incidents or environmental violations since its establishment, and all environmental protection facilities are operating normally[111]. Legal and Governance Issues - The company is involved in a lawsuit with Shanghai Lihui Equity Investment Partnership, with a disputed amount of CNY 14.18 million (approximately USD 2.1 million), which is currently under trial[121]. - The company has ongoing small claims litigation involving CNY 0.83 million (approximately USD 0.12 million), which is still in progress[121]. - There were no related party transactions during the reporting period, including asset or equity acquisitions[124][125]. - The company did not engage in any violations regarding external guarantees during the reporting period[118]. - The semi-annual financial report has not been audited[119]. - The company has not undergone any bankruptcy reorganization during the reporting period[120].

Core Viewpoint - The company is expected to achieve a net profit of 170 million to 185 million yuan in the first half of 2025, reflecting a year-on-year growth of 13.92% to 23.97%, maintaining its leading position in the field of allergic disease treatment [1] Group 1: Product Performance - The core product "Dust Mite Drops" continues to show strong growth, with sales revenue reaching 455 million yuan, a year-on-year increase of 10.51% [2] - The sales revenue of "Artemisia Pollen Allergen Sublingual Drops" is 21 million yuan, growing by 71.37% year-on-year, while "Skin Prick Test Solution" sales reached 6.3 million yuan, up 104.38% year-on-year, driven by increased market promotion efforts [2] Group 2: Innovation and R&D - The company is increasing its investment in innovative R&D, with multiple projects making significant progress, including the expansion of its allergen product pipeline [3] - New products such as "Sycamore Pollen Allergen Skin Prick Solution" and "German Cockroach Allergen Skin Prick Solution" have received approval for market application, enhancing the product pipeline [3] Group 3: Industry Environment - The incidence of allergic diseases is rising in China, driven by increased health awareness and environmental changes, leading to growing medical demand and technological advancements in the field [4] - The "Healthy China 2030" strategy emphasizes the prevention and treatment of allergic diseases, with desensitization therapy recognized as a key method, promoting clinical application and market expansion of related products [4] Group 4: Operational Quality - The company has optimized production processes and strengthened cost control, maintaining a high level of profitability and improving operational cash flow, indicating good financial health [5] - The company plans to continue focusing on the allergic disease field and accelerate the launch of in-development products, with expectations for sustained growth in performance [5] Group 5: Overall Performance Outlook - The company's performance in the first half of 2025 aligns with market expectations, showcasing resilience and a promising future driven by core product growth and innovation strategies [6]

格隆汇8月12日丨我武生物(300357.SZ)公布，公司于近日收到浙江省药品监督管理局换发的《药品生产 许可证》，换发后的《药品生产许可证》的有效期至2030年8月10日。本次《药品生产许可证》换发是 由于原许可证即将到期，新证的取得确保了公司的正常生产经营。 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-026 号 浙江我武生物科技股份有限公司 关于取得换发的药品生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 分类码：Asc 注册地址：浙江省德清县武康镇志远北路 636 号 法定代表人：胡赓熙 企业负责人：毕自强 质量负责人：马荣水 质量受权人：马荣水 浙江我武生物科技股份有限公司（以下简称"公司"）于近日收到浙江省药 品监督管理局换发的《药品生产许可证》，换发后的《药品生产许可证》的有效 期至 2030 年 8 月 10 日，相关主要信息如下： 一、《药品生产许可证》主要信息 企业名称：浙江我武生物科技股份有限公司 许可证编号：浙 20050116 社会信用代码：91330000742906207U 生产负责人：夏道林 有效期至：2030 年 8 月 10 日 生产地址和生产范围：浙江省德清县武康镇志远北路 636 号：体内诊断试剂 （变应原皮肤点刺试验对照液、屋尘螨皮肤点刺诊断试剂盒、德国小蠊变应原皮 肤点刺液、悬铃木花粉变应原皮肤点刺液、狗毛皮屑点刺液、猫毛皮屑变应原皮 肤 ...

从资金流向上来看，当日生物制品板块主力资金净流出7.15亿元，游资资金净流入1.03亿元，散户资金净 流入6.12亿元。生物制品板块个股资金流向见下表： 证券之星消息，8月12日生物制品板块较上一交易日下跌0.65%，科兴制药领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600211 | 西藏药业 | 48.04 | 10.01% | 17.50万 | | 8.33亿 | | 300357 | 我武生物 | 26.60 | 2.19% | 11.16万 | | 2.91亿 | | 002007 | 华兰生物 | 17.06 | 1.73% | 36.57万 | | 6.30亿 | | 301080 | 百普赛斯 | 54.16 | 0.86% | 2.12万 | | 1.14亿 | | 002581 | ST未名 | 7.27 | 0.83% | ...

Core Viewpoint - The company has initiated the first subject enrollment for the Phase I clinical trial of the "Dermatitis Diagnostic Patch 02" aimed at exploring its safety in patients with allergic contact dermatitis in China [1] Group 1: Product Development - The "Dermatitis Diagnostic Patch 02" is designed for patch testing to assist in diagnosing allergic contact dermatitis related to sensitizers such as carso, p-phenylenediamine, and formaldehyde [1] - This product expands the company's research pipeline in the field of allergic disease diagnostics, potentially addressing the allergen detection needs of a broader range of allergic disease patients [1] Group 2: Clinical Trial Progress - The product has officially entered Phase I clinical trials, although the results of these trials carry uncertainties [1] - Subsequent phases, including Phase II, Phase III clinical trials, and the application for market approval, will follow before the product can be commercially available, with progress and outcomes remaining uncertain [1]

Core Insights - The company I-Woo Biotech announced the initiation of a Phase I clinical trial for its "Dermatitis Diagnostic Patch 02" at Jining First People's Hospital, marking the enrollment of the first subject in the study [1] Company Summary - I-Woo Biotech has developed a dermatitis diagnostic patch aimed at patients with allergic contact dermatitis [1] - The clinical trial is focused on exploring the safety of the patch in the specified patient population [1]

产品名称：皮炎诊断贴剂02贴 注册分类：治疗用生物制品1类 剂型：贴剂 证券代码：300357 证券简称：我武生物 公告编号：2025-025 号 浙江我武生物科技股份有限公司 关于皮炎诊断贴剂 02 贴 I 期临床试验首例受试者入组公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 日前，浙江我武生物科技股份有限公司（以下简称"公司"）研发的"皮炎 诊断贴剂 02 贴"（以下简称"本品"） 在济宁市第一人民医院完成了"一项在 中国变应性接触性皮炎患者中探索皮炎诊断贴剂 02 贴安全性的 I 期临床研究" 的首例受试者入组，正式进入该临床试验。现将有关内容公告如下： 一、基本情况 截至本公告披露日，经查询国家药品监督管理局网站，获得国家药品监督管 理局批准上市的皮炎诊断贴剂产品为SmartPractice Denmark ApS的"皮炎诊断贴 剂（24）"（商品名：曲泰斯，注册证号：国药准字SJ20150015），其包含了例 1 如Cl+Me-异噻唑啉酮、对苯二胺、甲醛等24种常见过敏原。 申请适应症：用于斑贴试验，辅助诊断与卡松、对苯二胺、甲醛致敏相关的 ...